ATE337413T1 - Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen - Google Patents

Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen

Info

Publication number
ATE337413T1
ATE337413T1 AT00918364T AT00918364T ATE337413T1 AT E337413 T1 ATE337413 T1 AT E337413T1 AT 00918364 T AT00918364 T AT 00918364T AT 00918364 T AT00918364 T AT 00918364T AT E337413 T1 ATE337413 T1 AT E337413T1
Authority
AT
Austria
Prior art keywords
precancer
cancer
methods
specificity
sensitivity
Prior art date
Application number
AT00918364T
Other languages
English (en)
Inventor
Stanley N Lapidus
Anthony P Shuber
Original Assignee
Exact Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exact Sciences Corp filed Critical Exact Sciences Corp
Application granted granted Critical
Publication of ATE337413T1 publication Critical patent/ATE337413T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00918364T 1999-03-26 2000-03-24 Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen ATE337413T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/277,016 US6143529A (en) 1996-08-14 1999-03-26 Methods for improving sensitivity and specificity of screening assays

Publications (1)

Publication Number Publication Date
ATE337413T1 true ATE337413T1 (de) 2006-09-15

Family

ID=23059077

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918364T ATE337413T1 (de) 1999-03-26 2000-03-24 Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen

Country Status (8)

Country Link
US (1) US6143529A (de)
EP (1) EP1185693B1 (de)
JP (3) JP2002539848A (de)
AT (1) ATE337413T1 (de)
AU (1) AU761722B2 (de)
CA (1) CA2369045C (de)
DE (1) DE60030281T2 (de)
WO (1) WO2000058514A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
US6268136B1 (en) * 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6818404B2 (en) * 1997-10-23 2004-11-16 Exact Sciences Corporation Methods for detecting hypermethylated nucleic acid in heterogeneous biological samples
AU752817B2 (en) 1999-02-25 2002-10-03 Exact Sciences Corporation Methods for preserving DNA integrity
EP1169479B1 (de) * 1999-04-09 2006-06-28 EXACT Sciences Corporation Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US6849403B1 (en) * 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6919174B1 (en) * 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
CA2394921A1 (en) 1999-12-07 2001-06-14 Anthony P. Shuber Supracolonic aerodigestive neoplasm detection
US7250252B2 (en) * 1999-12-30 2007-07-31 David Aaron Katz Amplification based polymorphism detection
US6585646B2 (en) * 2000-11-29 2003-07-01 Hermetic Diagnostics, Inc. Screening test and procedure using skin patches
US6911308B2 (en) * 2001-01-05 2005-06-28 Exact Sciences Corporation Methods for detecting, grading or monitoring an H. pylori infection
US6428964B1 (en) 2001-03-15 2002-08-06 Exact Sciences Corporation Method for alteration detection
US6727354B2 (en) * 2001-12-12 2004-04-27 Quest Diagnostics Investments, Inc. Compositions and methods for TIGR genotyping assays
US20030180765A1 (en) * 2002-02-01 2003-09-25 The Johns Hopkins University Digital amplification for detection of mismatch repair deficient tumor cells
US7776524B2 (en) 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
WO2004074518A1 (en) * 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
ITMI20030434A1 (it) 2003-03-07 2004-09-08 Istituto Oncologico Romagnolo Coope Rativa Sociale Metodo per l'individuazione di tumori del colon-retto.
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
AU2004258085B2 (en) * 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
AU2004309396B2 (en) * 2003-12-23 2010-05-13 Genomic Health, Inc. Universal amplification of fragmented RNA
ES2636470T3 (es) * 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
WO2005108621A1 (en) * 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
WO2006026654A2 (en) 2004-08-27 2006-03-09 Exact Sciences Corporation Method for detecting a recombinant event
CA2584723A1 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス, インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
WO2006094149A2 (en) * 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
US20070248546A1 (en) * 2005-11-09 2007-10-25 Exact Sciences Corporation Clinical algorithm for excluding patients identified in virtual imaging
JPWO2008090930A1 (ja) * 2007-01-23 2010-05-20 オリンパス株式会社 癌の診断方法
JP5566111B2 (ja) * 2007-11-20 2014-08-06 オリンパス株式会社 Rna回収方法
EP2816122A1 (de) 2008-02-15 2014-12-24 Mayo Foundation For Medical Education And Research Neoplasmanachweis von einer Stuhlprobe
GB201107466D0 (en) 2011-05-05 2011-06-15 Loktionov Alexandre Device and method for non-invasive collection of colorectal mucocellular layer and disease detection
US9341628B2 (en) 2012-11-30 2016-05-17 Interpace Diagnostics Corporation Methods for measuring carcinoembryonic antigen
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
JP6294614B2 (ja) 2013-05-08 2018-03-14 有限会社マイテック 癌関連物質の定量方法
US10253358B2 (en) 2013-11-04 2019-04-09 Exact Sciences Development Company, Llc Multiple-control calibrators for DNA quantitation
US10138524B2 (en) 2013-12-19 2018-11-27 Exact Sciences Development Company, Llc Synthetic nucleic acid control molecules
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
CN114574585A (zh) 2015-08-31 2022-06-03 梅约医药教育及研究基金会 检测胃肿瘤
WO2018017710A1 (en) 2016-07-19 2018-01-25 Exact Sciences Development Company, Llc Nucleic acid control molecules from non-human organisms
EP3978624B1 (de) 2016-07-19 2025-03-26 Exact Sciences Corporation Methylierte kontroll-dna

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE501439C2 (sv) * 1993-06-22 1995-02-13 Pharmacia Lkb Biotech Sätt och anordning för analys av polynukleotidsekvenser
EP0871768B1 (de) * 1995-03-17 2004-07-07 John Wayne Cancer Institute Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen

Also Published As

Publication number Publication date
WO2000058514A2 (en) 2000-10-05
JP2002539848A (ja) 2002-11-26
JP2010172347A (ja) 2010-08-12
US6143529A (en) 2000-11-07
CA2369045C (en) 2010-06-01
EP1185693B1 (de) 2006-08-23
WO2000058514A3 (en) 2001-12-13
JP2013116131A (ja) 2013-06-13
DE60030281T2 (de) 2007-08-30
AU3918900A (en) 2000-10-16
AU761722B2 (en) 2003-06-05
CA2369045A1 (en) 2000-10-05
DE60030281D1 (de) 2006-10-05
EP1185693A2 (de) 2002-03-13

Similar Documents

Publication Publication Date Title
ATE337413T1 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
DK1381697T3 (da) Cirkulær probe-amplifikation (CPA) af ringformede nukleinsyremolekyler
ATE331811T1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
DE69938662D1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
DE50304023D1 (de) Diagnose von Myokardinfarkt und akutem Koronarsyndrom durch Kombination von Markern
DE60029369D1 (de) Verfahren und Sondenset zur Erkennung von Krebs
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
ATE452989T1 (de) Zusammensetzungen und methoden zur identifizierung von krebszellen
ATE269974T1 (de) Identifizierung und charakterisierung von interagierenden molekülen mittels automatisierter interagierender paarung
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
DE602005013998D1 (de) Verfahren und reagenzien zur erkennung von melanomen
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE60027045D1 (de) Oligonukleotide und diese enthaltende komplexe zur detektion der anwesenheit oder abwesenheit einer zielnukleinsäure in einer probe
SE8802944L (sv) Material foer lapptestning
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE478337T1 (de) Methoden zum nachweis analyten in proben
WO2003008635A8 (en) η-SECRETASE IN VITRO SCREENING ASSAY
ATE449868T1 (de) Methoden, testsätze und kompositionen zur detektion und quantifizierung von zielsequenzen
SE0004334D0 (sv) Electron spectroscopy
ATE482283T1 (de) Verfahren, biosensoren und kits zum nachweis und zur identifizierung von pilzen
DE60229513D1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
HUP0400130A2 (en) Scintillation proximity assays for aminoglycoside binding molecules
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
DE59910326D1 (de) Verwendung derivatisierter Reagenzien in Chemilumineszenz- und Elektrochemilumineszenz-Nachweisverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties